2024 - 2032 年癌胚抗原 (CEA) 市场机会、成长动力、产业趋势分析与预测

Carcinoembryonic Antigen (CEA) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年09月30日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球癌胚抗原(CEA) 市场估值为22 亿美元，预计2024 年至2032 年复合年增长率为6.3%。的。据世界卫生组织 (WHO) 称，全球癌症负担预计将激增，到 2040 年预计将有约 2700 万新发病例和 1600 万癌症相关死亡。占所有癌症诊断的首位，在癌症相关死亡率中排名第二。癌症盛行率的增加刺激了对 CEA 检测的需求，这对于监测治疗反应、检测復发和帮助早期诊断至关重要。根据应用，CEA 市场分为胃肠癌、乳癌、肺癌、卵巢癌、前列腺癌和甲状腺癌。

到 2023 年，胃肠癌细分市场将占据市场主导地位，占据 41.4% 的份额，预计在预测期内将以 6.7% 的复合年增长率增长。该细分市场涵盖各种癌症，包括结直肠癌、胰腺癌、肝癌、胃癌、食道癌、胆囊癌和肛门癌，CEA 测试在监测这些疾病方面发挥着至关重要的作用。该市场也按性别分类，到2023 年，男性细分市场将占据54.8% 的可观份额。的盛行率很高。虽然 CEA 不是前列腺癌的主要生物标记物，但它经常与其他诊断方法一起使用，以追踪疾病进展和治疗结果，使其成为男性癌症护理的宝贵工具。，到2023 年将产生8.301 亿美元的收入，预计未来几年将大幅成长。美国市场的主导地位可归因于其先进的医疗基础设施、胃肠道癌症的高盛行率以及持续的研究工作。此外，该国在诊断创新方面的领先地位提高了 CEA 检测的准确性和可靠性，进一步推动了该地区市场的成长。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	22亿美元
预测值	38亿美元
复合年增长率	6.3%

产业生态系统
产业影响力
- 成长动力
  - 癌症盛行率上升
  - 对微创诊断程序的需求不断增长
  - 癌胚抗原诊断的最新技术进展
  - 人均医疗保健支出增加
- 产业陷阱与挑战
  - 无法检测早期癌症
  - 对癌胚抗原检测的应用缺乏认识
成长潜力分析
监管环境
- 我们
- 欧洲
2023 年全球主要癌症发生率（按地区）
- 北美癌症发生率
- 欧洲癌症发生率
- 亚太地区癌症发生率
- 拉丁美洲癌症发生率
- 中东和非洲癌症发生率
临床研究景观
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
- F. Hoffmann-La Roche Ltd.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
主要市场参与者的竞争分析
公司矩阵分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
胃肠癌
- 大肠直肠癌
- 胰腺癌
- 肝癌
- 胃癌
- 食道癌
- 胆囊癌
- 肛门癌
乳癌
肺癌
卵巢癌
摄护腺癌
甲状腺癌

第 6 章：市场估计与预测：按性别划分，2021 - 2032 年

主要趋势
男性
女性

第 7 章：市场估计与预测：按最终用户划分，2021 - 2032 年

主要趋势
医院
诊断实验室
肿瘤诊所
研究中心和学术机构

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 波兰
- 俄罗斯
- 瑞典
- 瑞士
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 纽西兰
- 马来西亚
- 新加坡
- 印尼
- 菲律宾
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 哥伦比亚
- 秘鲁
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abcam Limited
AdvaCare Pharma
Aviva Systems Biology Corporation
Boster Biological Technology
Creative Diagnostics
Diazyme Laboratories Inc.
F. Hoffmann-La Roche Ltd.
Medix Biochemica
Omega Diagnostics Ltd.
RayBiotech, Inc.
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated

简介目录

Product Code: 427

The Global Carcinoembryonic Antigen (CEA) Market was valued at USD 2.2 billion in 2023 and is projected to grow at a 6.3% CAGR from 2024 to 2032. The market expansion is largely driven by the rising incidence of cancers such as colorectal, lung, and breast cancers worldwide. According to the World Health Organization (WHO), the global cancer burden is expected to surge, with around 27 million new cases and 16 million cancer-related deaths anticipated by 2040. Colorectal cancer is the third most common type globally, accounting for 10% of all cancer diagnoses and ranking second in cancer-related mortality. The increasing cancer prevalence has fueled the demand for CEA tests, which are essential for monitoring treatment responses, detecting recurrences, and aiding in early diagnosis. By application, the CEA market is segmented into gastrointestinal, breast, lung, ovarian, prostate, and thyroid cancers.

The gastrointestinal cancer segment dominated the market in 2023, holding a 41.4% share and is expected to grow at a 6.7% CAGR over the forecast period. This segment encompasses various cancers, including colorectal, pancreatic, liver, stomach, esophageal, gall bladder, and anal cancers, with CEA tests playing a crucial role in monitoring these conditions. The market is also categorized by gender, with the male segment capturing a substantial share of 54.8% in 2023. This segment is projected to reach a market size of USD 2.1 billion by 2032. The high prevalence of cancers such as colorectal, lung, and prostate cancers in men has led to increased adoption of CEA testing. While CEA is not the primary biomarker for prostate cancer, it is frequently used alongside other diagnostics to track disease progression and treatment outcomes, making it a valuable tool in men's cancer care.In terms of regional analysis, the U.S. led the North American CEA market, generating USD 830.1 million in revenue in 2023, with significant growth expected over the coming years. The U.S. market's dominance can be attributed to its advanced healthcare infrastructure, high prevalence of gastrointestinal cancers, and ongoing research efforts. Additionally, the country's leadership in diagnostic innovation has enhanced the accuracy and reliability of CEA assays, further driving the market's growth in the region.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$2.2 Billion
Forecast Value	$3.8 Billion
CAGR	6.3%

Chapter 1 Methodology & Scope

1.1 Market segmentation
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculations
- 1.3.2 Key trends for market estimates
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising in cancer prevalence
  - 3.2.1.2 Growing demand for minimally invasive diagnostic procedures
  - 3.2.1.3 Recent technological advancements in carcinoembryonic antigen diagnostics
  - 3.2.1.4 Increasing per capita healthcare expenditure
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Inability to detect early-stage cancer
  - 3.2.2.2 Lack of awareness regarding the application of carcinoembryonic antigen tests
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
3.5 Global incidence of top cancers, by region, 2023
- 3.5.1 North America cancer incidence
- 3.5.2 Europe cancer incidence
- 3.5.3 Asia Pacific cancer incidence
- 3.5.4 Latin America cancer incidence
- 3.5.5 Middle East & Africa cancer incidence
3.6 Clinical studies landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
- 4.1.1 F. Hoffmann-La Roche Ltd.
- 4.1.2 Quest Diagnostics Incorporated
- 4.1.3 Thermo Fisher Scientific Inc.
4.2 Competitive analysis of major market players
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Gastrointestinal cancer
- 5.2.1 Colorectal cancer
- 5.2.2 Pancreatic cancer
- 5.2.3 Liver cancer
- 5.2.4 Stomach cancer
- 5.2.5 Esophageal cancer
- 5.2.6 Gall bladder cancer
- 5.2.7 Anal cancer
5.3 Breast cancer
5.4 Lung cancer
5.5 Ovarian cancer
5.6 Prostate cancer
5.7 Thyroid cancer

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Male
6.3 Female

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Oncology clinics
7.5 Research centers and academic institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Poland
- 8.3.7 Russia
- 8.3.8 Sweden
- 8.3.9 Switzerland
- 8.3.10 Netherlands
- 8.3.11 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 New Zealand
- 8.4.7 Malaysia
- 8.4.8 Singapore
- 8.4.9 Indonesia
- 8.4.10 Philippines
- 8.4.11 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Columbia
- 8.5.5 Peru
- 8.5.6 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa